We developed a multi-layered analysis that combined public disclosures, clinical trial pipelines, and funding announcements with proprietary mapping of US-based cell therapy CDMOs and internal manufacturing networks. Capacity modeling incorporated both autologous and allogeneic modalities, with sensitivity scenarios to test a range of assumptions and stress conditions. By synthesizing these diverse inputs, we produced a structured view of the market that offered clarity on a subject where published information was otherwise incomplete or conflicting.